Table 2.
Association of prediagnostic low serum pepsinogen I and subsequent gastric cancer risk in the ATBC Study
| number of cases | person years | model 1 | model 2 | |||
|---|---|---|---|---|---|---|
| HR | 95% CI | HR | 95% CI | |||
| Gastric cancer total | 329 | 5,724 | 2.53 | 1.89–3.37 | 2.68 | 1.99–3.61 |
| Anatomical subsite | ||||||
| Noncardia | 245 | 4,274 | 2.76 | 1.99–3.83 | 2.95 | 2.11–4.12 |
| Cardia | 84 | 1,449 | 1.93 | 1.04–3.59 | 2.01 | 1.05–3.83 |
| Lauren classification | ||||||
| Intestinal | 115 | 1,759 | 2.33 | 1.43–3.81 | 2.57 | 1.57–4.21 |
| Diffuse | 63 | 1,101 | 1.04 | 0.41–2.61 | 0.92 | 0.33–2.55 |
| Others | 151 | 2,864 | 3.49 | 2.35–5.17 | 3.74 | 2.49–5.61 |
Abbreviations: ATBC - Alpha-Tocopherol, Beta-Carotene Cancer Prevention, HR – hazard ratio, CI – confidence interval
model 1: adjusted for age at randomization and type of intervention
model 2: model 1 + body mass index, pack years of smoking, alcohol drinking, education, fruit intake, and vegetable intake